Expression and regulatory mechanism of microRNA-133 in tumor

doi:10.3760/cma.j.issn.1673-422X.2014.09.001

Abstract

Abstract: As small non-coding RNAs, microRNAs (miRNAs) have been recognized as important regulatory factors in the posttranscription regulation network. Studies have shown that miR-133a and miR-133b, as members of miR-133 family, can regulate the expression of target genes such as epidermal growth factor receptor and oncogene. They regulate the mitogen-activated protein kinases and protein kinase B signaling pathways, which affect tumor cell proliferation, invasion and migration. MiR-133 plays a key role in the process of tumor development and progression, suggesting that it could be served as a new target for cancer treatment.

Key words: MicroRNAs, Neoplasms, Neoplasm metastasis, Signal transduction

Zhang Yue, Zhao Liang. Expression and regulatory mechanism of microRNA-133 in tumor[J]. Journal of International Oncology, 2014, 41(8): 641-644.

References

［1］ Chen WS, Leung CM, Pan HW, et al. Silencing of miR11 and miR133a2 cluster expression by DNA hypermethylation in colorectal cancer［J］. Oncol Rep, 2012, 28 (3): 1069-1076. ［2］ Tao J, Wu D, Xu B, et al. microRNA133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor［J］. Oncol Rep, 2012, 27(6): 1967-1975. ［3］ Kojima S, Chiyomaru T, Kawakami K, et al. Tumour suppressors miR1 and miR133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer［J］. Br J Cancer, 2012, 106(2): 405-413. ［4］ Kano M, Seki N, Kikkawa N, et al. miR145, miR133a and miR133b: tumorsuppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma［J］. Int J Cancer, 2010, 127(12): 2804-2814. ［5］ Kawakami K, Enokida H, Chiyomaru T, et al. The functional significance of miR1 and miR133a in renal cell carcinoma［J］. Eur J Cancer, 2012, 48(6): 827-836. ［6］ Chiyomaru T, Enokida H, Tatarano S, et al. miR145 and miR133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer［J］. Br J Cancer, 2010, 102(5): 883-891. ［7］ Cui Q, Yu Z, Purisima EO, et al. Principles of microRNA regulation of a human cellular signaling network［J］. Mol Syst Biol, 2006, 2: 46. ［8］ Mutallip M, Nohata N, Hanazawa T, et al. Glutathione Stransferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR133alpha in head and neck squamous cell carcinoma (HNSCC)［J］. Int J Mol Med, 2011, 27(3): 345-352. ［9］ Nohata N, Hanazawa T, Kikkawa N, et al. Caveolin1 mediates tumor cell migration and invasion and its regulation by miR133a in head and neck squamous cell carcinoma［J］. Int J Oncol, 2011, 38(1): 209-217. ［10］ Wang H, An H, Wang B, et al. miR133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway［J］. Eur J Cancer, 2013, 49(18): 3924-3935. ［11］ Cui W, Zhang S, Shan C, et al. microRNA133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway［J］. FEBS J, 2013, 280(16): 3962-3974. ［12］ Moriya Y, Nohata N, Kinoshita T, et al. Tumor suppressive microRNA133a regulates novel molecular networks in lung squamous cell carcinoma［J］. J Hum Genet, 2012, 57(1): 38-45. ［13］ Wen D, Li S, Ji F, et al. miR133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer［J］. Tumour Biol, 2013, 34(2): 793-803. ［14］ Hu G, Chen D, Li X, et al. miR133b regulates the MET protooncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo［J］. Cancer Biol Ther, 2010, 10(2): 190-197. ［15］ Wong TS, Liu XB, ChungWai Ho A, et al. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling［J］. Int J Cancer, 2008, 123(2): 251-257. ［16］ Qin W, Dong P, Ma C, et al. MicroRNA133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways［J］. Oncogene, 2012, 31(36): 4067-4075. ［17］ Crawford M, Batte K, Yu L, et al. MicroRNA 133B targets prosurvival molecules MCL1 and BCL2L2 in lung cancer［J］. Biochem Biophys Res Commun, 2009, 388(3): 483-489. ［18］ Liu L, Shao X, Gao W, et al. MicroRNA133b inhibits the growth of nonsmallcell lung cancer by targeting the epidermal growth factor receptor［J］. FEBS J, 2012, 279(20): 3800-3812. ［19］ Chiyomaru T, Enokida H, Kawakami K, et al. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer［J］. Urol Oncol, 2012, 30(4): 434-443. ［20］ Yoshino H, Chiyomaru T, Enokida H, et al. The tumoursuppressive function of miR1 and miR133a targeting TAGLN2 in bladder cancer［J］. Br J Cancer, 2011, 104(5): 808-818. ［21］ Nohata N, Hanazawa T, Kikkawa N, et al. Identification of novel molecular targets regulated by tumor suppressive miR1/miR133a in maxillary sinus squamous cell carcinoma［J］. Int J Oncol, 2011, 39(5): 1099-1107. ［22］ Uchida Y, Chiyomaru T, Enokida H, et al. MiR133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines［J］. Urol Oncol, 2013, 31(1): 115-123. ［23］ SainzJaspeado M, LagaresTena L, Lasheras J, et al. Caveolin1 modulates the ability of Ewing′s sarcoma to metastasize［J］. Mol Cancer Res, 2010, 8(11): 1489-1500. ［24］ Joshi B, Strugnell SS, Goetz JG, et al. Phosphorylated caveolin1 regulates Rho/ROCKdependent focal adhesion dynamics and tumor cell migration and invasion［J］. Cancer Res, 2008, 68(20): 8210-8220. ［25］ Zhao L, Wang H, Liu C, et al. Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1［J］. Gut, 2010, 59(9): 1226-1235. ［26］ Kinoshita T, Nohata N, WatanabeTakano H, et al. Actinrelated protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumorsuppressive microRNA133a in head and neck squamous cell carcinoma［J］. Int J Oncol, 2012, 40(6): 1770-1778. ［27］ Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated by the miR133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma［J］. Oncol Rep, 2012, 28(2): 465-472. ［28］ Yamamoto H, Kohashi K, Fujita A, et al. Fascin1 overexpression and miR133b downregulation in the progression of gastrointestinal stromal tumor［J］. Mod Pathol, 2013, 26(4): 563-571. ［29］ Gan Y, Shi C, Inge L, et al. Differential roles of ERK and Akt pathways in regulation of EGFRmediated signaling and motility in prostate cancer cells［J］. Oncogene, 2010, 29(35): 4947-4958. ［30］ PljesaErcegovac M, SavicRadojevic A, Dragicevic D, et al. Enhanced GSTP1 expression in transitional cell carcinoma of urinary bladder is associated with altered apoptotic pathways［J］. Urol Oncol, 2011, 29(1): 70-77. ［31］ Xie JJ, Xu LY, Zhang HH, et al. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells［J］. Biochem Biophys Res Commun, 2005, 337(1): 355-362. ［32］ Vignjevic D, Schoumacher M, Gavert N, et al. Fascin, a novel target of betacateninTCF signaling, is expressed at the invasive front of human colon cancer［J］. Cancer Res, 2007, 67(14): 6844-6853.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.